Antidepressant efficacy for depression in children and adolescents: Industry- and NIMH-funded studies

American Journal of Psychiatry

Volumn 174, Issue 5, 2017, Pages 430-437

  Walkup, John T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ANXIETY DISORDER; CHILD; COGNITIVE BEHAVIORAL THERAPY; DEPRESSION; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EFFECT SIZE; FUNDING; HUMAN; OBSESSIVE COMPULSIVE DISORDER; PATIENT PARTICIPATION; PLACEBO EFFECT; REVIEW; VULNERABLE POPULATION; ANXIETY DISORDERS; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DEPRESSIVE DISORDER; FINANCIAL MANAGEMENT; META ANALYSIS (TOPIC); METHODOLOGY; NATIONAL HEALTH ORGANIZATION; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CHILD; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DRUG INDUSTRY; FINANCING, GOVERNMENT; FINANCING, ORGANIZED; HUMANS; META-ANALYSIS AS TOPIC; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); OBSESSIVE-COMPULSIVE DISORDER; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

EID: 85018389070     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.16091059     Document Type: Review

References (36)

1. Cipriani A, Zhou X, Del Giovane C, et al: Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: A network meta-analysis. Lancet 2016; 388: 881-890
2. Jureidini J: Antidepressants fail, but no cause for therapeutic gloom. Lancet 2016; 388:844-845
3. Kirsch I: The emperor's new drugs: medication and placebo in the treatment of depression. Handb Exp Pharmacol 2014; 225: 291-303
4. Thaul S: FDA's authority to ensure that drugs prescribed to children are safe and effective. Washington, DC, Congressional Research Service, June 25, 2012 (https://www.fas.org/sgp/crs/misc/RL33986.pdf )
5. US Food and Drug Administration (FDA): Full text of the Food and Drug Modernization Act. Silver Spring, Md, FDA, Nov 21, 1997 (http://www.fda.gov/RegulatoryInformation/Legislation/Significant AmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm)
6. Arndt M: Eli Lilly: life after Prozac: as the drug goes off-patent, all-out R&D is paying off. BloombergBusinessweek, Jul 23, 2001 (http://www.bloomberg.com/news/articles/2001-07-22/eli-lilly-lifeafter-prozac)
7. US Food and Drug Administration (FDA): The Pediatric Exclusivity Provision: January 2001 Status Report to Congress. Silver Spring, Md, FDA, Jan 2001 (http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049915.pdf )
8. March J, Silva S, Petrycki S, et al: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807-820
9. Emslie GJ, Rush AJ, Weinberg WA, et al: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54:1031-1037
10. Emslie GJ, Heiligenstein JH, Wagner KD, et al: Fluoxetine for acute treatment of depression in children and adolescents: A placebocontrolled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41:1205-1215
11. Keller MB, Ryan ND, Strober M, et al: Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40:762-772
12. Berard R, Fong R, Carpenter DJ, et al: An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2006; 16: 59-75
13. Emslie GJ, Wagner KD, Kutcher S, et al: Paroxetine treatment in children and adolescents with major depressive disorder: A randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2006; 45:709-719
14. Wagner KD, Ambrosini P, Rynn M, et al: Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290: 1033-1041
15. Wagner KD, Robb AS, Findling RL, et al: A randomized, placebocontrolled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004; 161: 1079-1083
16. vonKnorring AL,OlssonGI, Thomsen PH, et al:Arandomized, doubleblind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 2006; 26:311-315
17. Wagner KD, Jonas J, Findling RL, et al: A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006; 45:280-288
18. Emslie GJ, Ventura D, Korotzer A, et al: Escitalopram in the treatment of adolescent depression: A randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 2009; 48: 721-729
19. Emslie GJ, Findling RL, Yeung PP, et al: Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J AmAcad Child Adolesc Psychiatry 2007; 46:479-488
20. Atkinson SD, Prakash A, Zhang Q, et al: A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2014; 24:180-189
21. Emslie GJ, Prakash A, Zhang Q, et al: A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2014; 24:170-179
22. DelBello MP, Hochadel TJ, Portland KB, et al: A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents. J Child Adolesc Psychopharmacol 2014; 24: 311-317
23. US Food and Drug Administration: Review and Evaluation of Clinical Data (NDA 20-152; supplement S-032; sponsor: Bristol-Myers Squibb; drug: nefazodone hydrochloride [Serzone]; material submitted: Pediatric Exclusivity Supplement; date submitted: 4-16-02; PDUFA due date: 10-17-02; reviewer: Andrew D Mosholder, MD, MPH) (2-page version) (http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM164073.pdf )
24. US Food andDrugAdministration: Pediatric Supplement (NDA20-415; supplement SE5-011; sponsor: Organon; drug: mirtazapine [Remeron]; material submitted: Pediatric Supplement SE5-011; date submitted: 5/1/01; date received: 5/7/01; user fee due date: 3/7/02; medical reviewer: Ann-Kathryn Maust, MD) (http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM164066.pdf )
25. US Food and Drug Administration: Pediatric Exclusivity Granted November 2016 (http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM514985.pdf )
26. Zaccara G, Giovannelli F, Schmidt D: Placebo and nocebo responses in drug trials of epilepsy. Epilepsy Behav 2015; 43: 128-134
27. March JS, Silva S, Petrycki S, et al: The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64:1132-1143
28. Erratum in: Arch Gen Psychiatry 2008; 65:101
29. Brent D, Emslie G, Clarke G, et al: Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA 2008; 299:901-913
30. Vitiello B, Emslie G, Clarke G, et al: Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: A follow-up study of the TORDIA sample. J Clin Psychiatry 2011; 72:388-396
31. Goodyer IM, Dubicka B, Wilkinson P, et al: Arandomized controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors: The ADAPT trial. Health Technol Assess 2008; 12:iii-iv, ix-60
32. Brent DA, Greenhill LL, Compton S, et al: The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry 2009; 48:987-996
33. Strawn JR, Welge JA, Wehry AM, et al: Efficacy and tolerability of antidepressants in pediatric anxiety disorders: A systematic review and meta-analysis. Depress Anxiety 2015; 32:149-157
34. Bridge JA, Birmaher B, Iyengar S, et al: Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009; 166:42-49
35. Cytryn L, Gilbert A, Eisenberg L: The effectiveness of tranquilizing drugs plus supportive psychotherapy in treating behavior disorders of children: A double blind study of eighty outpatients. Am J Orthopsychiatry 1960; 30:113-129
36. US Food and Drug Administration: Review and Evaluation of Clinical Data (NDA 20-152; supplement S-032; sponsor: Bristol-Myers Squibb; drug: nefazodone hydrochloride (Serzone): material submitted: Pediatric Exclusivity Supplement; date submitted: 4-16-02. PDUFA due date: 10-17-02; reviewer: Andrew D. Mosholder, MD, MPH) (15-page redacted version). http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM376993.pdf